In the antibody-drug conjugates (ADCs) T-DM1 and T-DXd, trastuzumab acts as the monoclonal antibody (mAB) component, specifically recognizing and binding to the HER2 protein overexpressed on the surface of cancer cells. Here, ERBB2 is linked to cancer.